The aim of the study was to examine the pharmacokinetic and pharmacodynamic profiles of single doses of warfarin (25 mg ) following administration alone, and in combination with multiple doses of donepezil HCl (10 mg day −1 ) in healthy volunteers.
Introduction
synaptic concentrations of ACh, via the hydrolysis of AChE, thereby enhancing neurotransmission [1] [2] [3] . Clinical studies Donepezil HCl (also known as E2020 or AriceptA, the have shown that once-daily administration of donepezil can registered trademark of Eisai Co. Ltd, Tokyo, Japan) is a significantly improve both cognitive and global function in chemically distinct and well-tolerated inhibitor of the patients with Alzheimer's disease [4] [5] [6] [7] . enzyme acetylcholinesterase (AChE). It is used clinically for Warfarin is a coumarin anticoagulant that is widely used the symptomatic treatment of mild-moderate Alzheimer's in the treatment and prophylaxis of atrial fibrillation, stroke, disease. Current theories attribute the pathogenesis of the arterial and venous thrombosis [8] [9] [10] . The clinical effects cognitive symptoms of Alzheimer's disease to a deficiency of warfarin may be modified by several drugs. For example, in levels of the neurotransmitter acetylcholine (ACh) and a the hypo-prothrombinaemic effects of warfarin may be decrease in cholinergic neurotransmission. Donepezil is increased by concomitant administration with chloral hydrate postulated to produce its therapeutic effect by increasing [11, 12] , and marked increases in prothrombin times have been observed in patients taking phenylbutazone in addition to warfarin [13, 14] . Such interactions have historically been that is potentially relevant for drugs such as warfarin and Evans Medical) was administered on day 14 followed by 7 days of blood sampling. The subjects then completed a donepezil that are highly protein bound (99% [15] and 95.6% [16] , respectively). However, displacement from 3-week washout period, at the end of which they received another single 25 mg dose of warfarin. They then returned plasma proteins is rarely responsible for sustained changes in the plasma concentration of unbound drug, particularly for to the clinic for an additional 7 days for blood sampling. Treatment group B received no medication for the first drugs that are restrictively cleared, such as warfarin, as the concentration increase caused by displacement is buffered 13 days of the trial. A single dose of 25 mg warfarin was administered on day 14 followed by serial blood sampling by redistribution [17, 18] . Thus, although drug displacement does occur under certain circumstances for a number of for 7 days. After a further 7 days of washout, on day 28, subjects began 19 days of treatment with donepezil (5 mg highly protein-bound drugs, the effects of drug interactions are generally the result of other processes. For instance, once daily for the first week; 10 mg once daily thereafter), until day 47. A second dose of 25 mg of warfarin was given although phenylbutazone displaces warfarin from plasma proteins, observed changes in the pharmacodynamic response on day 41 (14 days after the start of donepezil treatment, as for group A) and blood sampling continued until day 47. of warfarin are due to inhibition of the metabolism of both its R-and, less potent, S-isomers [19, 20] . Similarly, the All study medication was taken at 08:00 h. Subjects were not allowed to take any other medication, including co-administration of non-steroidal anti-inflammatory agents causes the displacement of warfarin from plasma proteins prescription, non-prescription or investigational preparations during the study. Alcohol and caffeine-containing drinks and stereoselective inhibition of the metabolism of its (S)-enantiomer [21, 22] . and food were avoided from 12 h prior to the start until completion of each study period. Concomitant administration of warfarin and donepezil probably results in displacement from plasma protein binding, but this alone is unlikely to produce any clinically relevant Sample collection and analysis effects. Nevertheless, the possibility of other interactions between these two drugs that are clinically relevant cannot Warfarin was administered on days 14 and 41 of each treatment schedule. Blood samples for the determination of be ruled out. With this in mind, the present study was undertaken to examine the effects of multiple-dose adminisplasma levels of the (R)-and (S)-enantiomers were obtained just prior to drug administration and at 0.5, 1, 2, 4, 8, 12, tration of donepezil HCl (to approximate steady state) on the pharmacokinetic and pharmacodynamic profiles of 24, 36, 48, 60, 72, 96, 120 and 144 h after drug administration. warfarin.
Warfarin was analysed in plasma after solvent extraction followed by the formation of the diastereoisomers (R)-and Methods (S)-warfarin. The enantiomers were separated on a silica high-performance liquid chromatography (HPLC) column, The study was conducted in accordance with Good Clinical Practice Guidelines issued by the European Commission with post-column aminolysis and fluorescence detection. The lower limit of quantification for each of the diastereo-(1990). The protocol was approved by an independent ethics committee and written informed consent was obtained from isomers was 0.15 mg l −1 . The coefficients of variation were <15% for (R)-warfarin and <10% for (S)-warfarin. The each volunteer prior to entry. extent of bias at each concentration of the two enantiomers was ≤11%. Subjects
The study population comprised healthy male volunteers Pharmacokinetic assessments between 18 and 55 years of age who were within 15% of normal weight for their height and body build based on the Pharmacokinetic parameters were estimated separately for ( R)-warfarin and (S)-warfarin. Peak plasma concentration Metropolitan Insurance Company Height and Weight Tables  (1983) , and who were non-smokers. None of the subjects (C max ) and the time at which it occurred (t max ) were obtained from visual inspection of the plasma concenhad evidence of clinically significant disease of any major organ system. Those with a history of severe adverse drug tration-time curves. The terminal elimination rate constant (l z ) was estimated using Siphar Version 4.0 software (Simed, reactions or leucopenia, severe or multiple allergies, or habitual drug and/or alcohol abuse were specifically excluded Créteil, France). Exact sampling times were used in the calculations. from entering the trial, as were those who had participated in other clinical trials in the previous 3 months.
Total area under the plasma concentration-time curve (AUC (0-2 ) ) from time zero extrapolated to infinity was calculated as the sum of AUC , the area up to the last Protocol quantifiable time-point (144 h), and the area from the 144-h time-point extrapolated to infinity. AUC was This was an open-label, randomized, two-period, balanced, crossover study. Subjects who had fulfilled the entry criteria estimated by the trapezoidal approximation, and the extrapolated area was calculated from the final measurable concenat a screening visit, undertaken ≤2 weeks prior to entry, were randomized to one of two treatment groups, A or B.
tration divided by l z . The terminal half-life (t D ) was calculated as 0.693/l z , and Group A received donepezil for 19 days, at a dose of 5 mg once daily for the first week and 10 mg once daily thereafter.
the total apparent oral clearance (CL T /F) was calculated as dose divided by AUC (0-2 ) . The apparent volume of A single 25 mg dose of warfarin (5×5 mg MarevanA tablets, distribution (V lz /F) was calculated as the ratio of CL T /F Results to l z , where the factor F accounts for bioavailability. Subjects
Pharmacodynamic assessments
Thirteen healthy male volunteers with a median age of 28 years (range 18-55 years) entered the study. Their body Blood samples for the determination of prothrombin times weights ranged from 64 to 88 kg (median 72 kg) and their (Quick method) were taken at 0, 4, 12, 24, 36, 48, 60, 72, heights from 166 to 191 cm (median 175 cm). Twelve 96, 120 and 144 h after administration of warfarin. The subjects completed the study; one was withdrawn due to maximum prothrombin time (R max ) and the time of R max adverse events that included insomnia, headache and nausea. (t max ) were direct experimental observations. The area under the prothrombin time-time curve over the 144-h post-dose
Pharmacokinetics of warfarin period (AUC PT ) was estimated using the trapezoidal approximation. Prothrombin times are often reported as
The mean pharmacokinetic parameters for ( R)-and (S)-International Normalized Ratios (INR), i.e. the ratio of the warfarin alone, and in the presence of donepezil, averaged patient prothrombin time to the control prothrombin time, over all 12 subjects in both treatment groups are summarized raised to the power of the International Sensitivity Index in Table 1 . No statistically significant differences in warfarin (ISI). The ISI is the index of the reference thromboplastin pharmacokinetics were observed whether warfarin was used for the test compared with the World Health administered alone or concurrently with donepezil. When Organization reference reagent [23] . In this way, direct warfarin was administered in the absence of donepezil, ( R)-comparisons between laboratories are possible. However, in warfarin was seen to have a longer t D than (S)-warfarin this case, all blood samples for prothrombin times were (53.0±14.0 versus 37.0±35.0 h, respectively), and a greater analysed at one time using a single batch of thromboplastin.
AUC (0-2 ) (68.0±15.0 versus 51.0±59.0 mg h l −1 , respectTherefore, since the control prothrombin times were the ively). However, values for both enantiomers were not same for all samples, the INR and prothrombin values are significantly different in the presence of donepezil. proportional. Thus, it was not necessary to report the results As can be seen in Figure 1 , the plasma concentration-time as INR in this study, although the INR values are indicated profiles for the ( R)-and (S)-warfarin enantiomers in the on the prothrombin time curve.
presence and absence of donepezil are almost superimposable. The 90% confidence intervals for the ratios of C max and Safety assessments AUC (0-2 ) for ( R)-and (S)-warfarin in the presence of donepezil to their respective values for each enantiomer Safety was assessed by routine haematology and biochemistry alone were close to one ( Table 2 ). The seemingly high at screening, prior to warfarin administration and at the inter-subject variability for the t D and AUC (0-2 ) for (S)-post-study visit. Vital signs were monitored at entry, prior warfarin (Table 1) resulted from an unusually long t D of to drug administration on each dosing day, at 4, 8, 12, 24, 115 h in one of the subjects. This occurred in both treatment 36, 48, 60, 72, 96, 120 and 144 h after dosing with warfarin phases and may be due to atypical warfarin metabolism by in each study period, and at the post-study visit. Blood this subject. Analysis of variance detected a statistically pressure measurements were made in accordance with the British Hypertension Society guidelines. Readings were taken after the subjects had been sitting for 5 min and in the presence of donepezil relative to that for warfarin alone was 1.02 (90% confidence interval 0.96-1.08). The Table 2 The mean ratios (90% confidence intervals) of C max and corresponding mean ratio for AUC PT was 1.01 (90% AUC who had raised exposure to (S)-warfarin, as reflected by an AUC (0-2 ) of 226.8 mg h l −1 , had a prothrombin time
Mean ratio (90% confidence interval)
( R max =29.5 s) close to the mean value for the group. there an accompanying treatment-by-period interaction. Safety significant period effect for the AUC (0-2 ) of (S)-warfarin ( P=0.007), but there was no accompanying treatment-byBoth treatments were well tolerated and there were no clinically significant changes in vital signs, clinical laboratory period interaction ( P=0.576).
or ECG parameters during the course of this study. Those adverse events that were reported were transient and Pharmacodynamics of warfarin dissipated with continued drug administration. All were mild or moderate in intensity. These included reports of Measured values of prothrombin times are summarized in Table 3 , and the effect-time curves are shown in Figure 2 . nausea (n=18), vomiting (n=8) and headache (n=7). The pharmacodynamic parameters for warfarin (R max and AUC PT ) were virtually identical in the presence and absence Discussion of donepezil. R max values were 30.0±9.0 and 29.0±8.0 s, respectively, and AUC PT values were 3063±581 and In this study, the pharmacokinetics and pharmacodynamics of single doses of warfarin (25 mg ), administered alone, and 3032±602 s h, respectively. Furthermore, the prothrombin time curves for warfarin alone and for warfarin administered following multiple-dose administration (to approximate steady state) of donepezil HCl (10 mg day −1 ) in healthy with donepezil were virtually super-imposable (Figure 2) .
No statistically significant treatment effects were detected volunteers were examined.
No statistically significant differences in the pharmacoWe acknowledge the efforts of Drs P. E. probably does result in protein displacement interactions.
